Rege Nephro Co
Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options
$10.6MSeries C
Role not disclosedSA
SPARX Asset Management Co
Activity from announced rounds
Activity in this selectionSeries C+
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $160.6M 2 disclosed · full round size, not this investor’s share